Imbruvica Now Also Indicated for Children with Chronic Graft-versus-Host Disease.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 11, p. 34
- Publication type:
- Article
Works matching IS 21644403 AND DT 2022 AND VI 12 AND IP 11
Results: 19
1
2
Pemazyre Receives New Indication for FGFR1-Positive Myeloid/Lymphoid Neoplasms.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 11, p. 33
- Publication type:
- Article
3
Imfinzi Receives New FDA Indication for Advanced or Metastatic Biliary Tract Cancer.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 11, p. 33
- Publication type:
- Article
4
Retevmo Receives New FDA Indication for Advanced Solid Tumors with RET Fusion.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 11, p. 33
- Publication type:
- Article
5
Pedmark First Drug Approved for Hearing Loss Prevention in Children with Solid Tumors.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 11, p. 32
- Publication type:
- Article
6
Vegzelma a New Biosimilar FDA Approved for the Treatment of 6 Types of Malignancies.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 11, p. 32
- Publication type:
- Article
7
Lytgobi FDA Approved for Intrahepatic Cholangiocarcinoma with FGFR2 Fusion.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 11, p. 32
- Publication type:
- Article
8
Preservation of Liver Function in Patients with Metastatic iCCA with Extrahepatic Disease.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 11, p. 31
- Publication type:
- Article
9
International Cholangiocarcinoma Patient Registry Accelerates and Supports CCA Research.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 11, p. 30
- Publication type:
- Article
10
The Enduring Effects of the ACA on Disparities in Cancer Care.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 11, p. 28
- Publication type:
- Article
11
Generic and Biosimilar Drugs Generate a Record $373 Billion for America’s Patients and Healthcare System in 2021.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 11, p. 26
- Publication type:
- Article
12
Biosimilar Substitution May Reduce Financial Risk to Providers in Value-Based Payment Models.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 11, p. 25
- By:
- Publication type:
- Article
13
Increased Biosimilar Use Translates to Substantial Savings for Oncology Practices.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 11, p. 24
- By:
- Publication type:
- Article
14
Results from Phase 3 Trial Show Similar Efficacy and Safety Outcomes with CT-P16 versus Bevacizumab in Patients with NSCLC.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 11, p. 10
- By:
- Publication type:
- Article
15
Early Detection Blood Test May Change Cancer Screening Paradigms.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 11, p. 9
- By:
- Publication type:
- Article
16
INTERVIEW with the INNOVATERS.
- Published in:
- 2022
- Publication type:
- Interview
17
Implementing a Transportation Hub: A Holistic Approach to a Systemic Problem.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 11, p. 1
- Publication type:
- Article
18
The Cures Act Information Blocking Rule: Impact on Data Access, Interoperability, and Security.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 11, p. 1
- By:
- Publication type:
- Article
19
Overcoming Challenges in the Treatment of Primary Brain Tumors.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 11, p. 1
- By:
- Publication type:
- Article